Kintor Pharmaceutical Limited

Rentabilité sur six mois: +10.88%
Rendement en dividendes: 0%
Secteur: Healthcare

0.1774 $

0 $ +0%
0.0835 $
0.2089 $

paper.min_max_per_year

Calendrier des promotions Kintor Pharmaceutical Limited

À propos de l'entreprise Kintor Pharmaceutical Limited

Kintor Pharmaceutical Limited, a clinical-stage biotechnology company, engages in developing and commercializing a pipeline of small molecule and biological therapeutics for androgen-receptor-related disease areas with unmet medical needs in the People's Republic of China and internationally. The company's products pipeline include Proxalutamide, a second generation androgen receptor (AR) antagonist for the treatment of metastatic castration-resistant prostate cancer, AR positive breast cancer, and COVID-19; and Pyrilutamide, an AR antagonist for the androgenetic alopecia (AGA) and acne vulgaris treatment. Its products pipeline comprises ALK-1 antibody for the treatment of metastatic hepatocellular carcinoma (HCC) and various solid tumours; GT20029, a topical AR-PROTAC compound for the treatment of AGA and acne vulgaris; and PD-L1/TGF-ß, a dual target antibody to treat non-small cell lung cancer, biliary tract cancer, triple negative breast cancer, and HPV-associated tumours. In addition, the company's products pipeline include Detorsertib for the treatment of metastatic solid tumours, such as breast cancer, prostate cancer, and HCC; and Hedgehog/SMO Inhibitor, an inhibitor of the hedgehog signal transduction pathway to treat blood cancer. Kintor Pharmaceutical Limited was founded in 2009 and is headquartered in Suzhou, the People's Republic of China.

Paramètres de base

Industry
Biotechnology
Sector
Health Care
Валюта
usd
Валюта отчета
cny
Сайт

Grade

Sous-estimation
Nom Signification Grade
P/S 100.67 1
P/BV 1.71 8
P/E 0 0
Efficacité
Nom Signification Grade
ROA -22.44 0
ROE -41.29 0
ROIC 0 0
Dividendes
Nom Signification Grade
Rendement en dividendes 0 0
DSI 0 0
Croissance moyenne du dividende 0 0
Devoir
Nom Signification Grade
Debt/EBITDA -0.1248 10
Debt/Ratio 0.2558 10
Debt/Equity 0.7517 9
Impulsion de croissance
Nom Signification Grade
Rentabilité Revenue, % 616.33 10
Rentabilité Ebitda, % 366.98 10
Rentabilité EPS, % -75.49 0

paper.price.prices

Prix Common.min. Common.max. Changement paper.changes_in_industry paper.changes_in_index
common.calendar.number_days.1 0.1774 $ 0 $ 0 $ 0 % 0 % 0 %
common.calendar.number_days.7d 0.1774 $ 0 $ 0 $ 0 % 0 % 0 %
common.calendar.number_days.30d 0.1774 $ 0.1774 $ 0.1774 $ 0 % 0 % 0 %
common.calendar.number_days.90d 0.1774 $ 0.1774 $ 0.1774 $ 0 % 0 % 0 %
common.calendar.number_days.180d 0.16 $ 0.1441 $ 0.2089 $ 10.88 % 0 % 0 %
common.calendar.number_days.1y 0.0835 $ 0.0835 $ 0.2089 $ 112.46 % 0 % 0 %
common.calendar.number_days.3y 1.9 $ 0.0835 $ 3.9 $ -90.66 % 0 % 0 %
common.calendar.number_days.5y 0.0835 $ 0.0835 $ 11.8 $ 212.46 % 0 % 0 %
common.calendar.number_days.10y 0.0835 $ 0.0835 $ 11.8 $ 212.46 % 0 % 0 %
common.calendar.number_days.ytd 0.16 $ 0.1441 $ 0.2089 $ 10.88 % 0 % 0 %

Principaux propriétaires

Entreprises similaires



Gestion d'entreprise

Superviseur Titre d'emploi Paiement Année de naissance
Dr. Youzhi Tong Founder, CEO & Executive Chairman 983.28k 1962 (63 année)
Mr. Ming Ming Cheung Joint Company Secretary & CFO N/A 1977 (48 années)
Dr. Xiang Ni Chief Medical Officer & Executive Director N/A 1969 (56 années)
Mr. Wai Chiu Wong FCS Company Secretary N/A 1955 (70 années)

Informations sur l'entreprise

Adresse: China, Suzhou, No. 20 Songbei Road - Ouvrir dans google maps, Ouvrir les cartes yandex
Site web: https://www.kintor.com.cn